Pfizer, Haleon

Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer Further Pares Haleon Stake With £2.5 Billion Sale
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC,
Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.
Why Pfizer sold its $3 billion stake in Haleon
Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,
Pfizer to cut Haleon stake in 700M share sale
Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3%, implying a divestment of approximately 7.
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
STAT1d
Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...
BioSpace1d
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...